Amgen Inc.

Equities

AMGN

US0311621009

Market Closed - Nasdaq Other stock markets 21:00:00 20/01/2026 GMT			5-day change	1st Jan Change
331.00 ^USD	+0.18%		+2.07%	+1.13%

01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW

Transcript : Amgen Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01

Published on 12/03/2025 at 09:06 pm GMT - Modified on 12/03/2025 at 10:20 pm GMT

S&P Capital IQ

Presenter Speech
Geoffrey Meacham (Analysts)

Citi - 2025 Global Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. I have Jarwei Fang with me from my team as well. So

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Amgen Inc.

01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW
01-14	Honeywell Says Quantinuum Plans Confidential Filing of IPO Draft Registration	MT
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	Analyst recommendations: JPMorgan, Meta, Citigroup, BlackRock, AbbVie…
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-13	Alert incorrectly tagged to Rubicon Organics withdrawn	RE
01-13	The CPI That Changed Almost Nothing
01-13	Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage	RE
01-13	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-13	Amgen's Extension Study Shows MariTide Helped Maintain Weight Loss at Lower Dose, Less Frequency	MT
01-13	Focus on inflation and corporate earnings
01-13	Amgen Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
01-13	Amgen says MariTide helped trial patients maintain weight loss	RE
01-13	Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight	RE
01-12	Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed	RE
01-12	Amgen: "Large majority" of people in 52-week Maritide extension study given lower monthly dose or quarterly dose of drug maintained weight loss achieved in part 1 of phase 2 trial	RE
01-12	Amgen says 24-week study of monthly Maritide in people with type 2 diabetes showed robust, clinically meaningful reduction in both HbA1c, weight	RE
01-12	Amgen to announce data on obesity drug MariTide at healthcare conference	RE
01-12	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
01-12	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
01-12	Spyre Therapeutics, Inc. Appoints Kate Tansey Chevlen as Chief Commercial Officer	CI
01-12	Zymeworks Inc. Announces Management Changes	CI
01-08	Praxis Precision Medicines, Inc. Announces Management Changes	CI